Q1 FY27 revenue nearly doubles YoY but PAT plunges 95 percent

Revenue Growth 20pctResults RestatedResults View source PDF Explain this filing

BIOFILCHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹32.96

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-1.9% vs market

Pharmaceuticals peers, median of 165sector-0.6%-1.0% vs sector

On the reaction day the stock moved 1.9 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5+0.4-1.9-0.6-1.0

Next day

-1.4+0.5-2.0-0.3-1.1

-2.9+0.6-3.5-0.6-2.3

-3.9+0.7-4.6-1.4-2.5

-2.9+1.1-4.1-1.1-1.9

-6.1+0.5-6.6-1.9-4.1

-8.5+1.3-9.8-1.2-7.3

15d

-3.2+0.5-3.8-0.9-2.3

+0.5-0.8+1.3-0.4+0.9

-8.8-0.9-7.9-3.2-5.7

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Biofil posted Q1 FY27 revenue of Rs 12.35 crore, up 92 percent from Rs 6.43 crore YoY, driven by chemical division trading sales. However, PAT plunged to Rs 10.91 lakhs from Rs 241.10 lakhs on margin compression. Pharma division swung to a Rs 6.41 lakh loss versus Rs 269.74 lakh profit. The company is upgrading its manufacturing facility for Schedule M compliance, expected in 3 to 6 months.

Likely market impact

Strong topline growth offset by weak profitability. Manufacturing upgrade may pressure near-term margins but supports future sales.